
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon has demonstrated strong growth potential with a notable 11% sequential increase in gross business awards, driven by several significant wins with biotech customers and the expansion of partnerships with large pharmaceutical companies. The company has also exceeded its financial targets following the PRA acquisition and possesses a favorable client mix, positioning it well against uncertainties in funding environments. Furthermore, Icon is poised to accelerate clinical trial research in a rapidly growing contract research organization (CRO) market, supported by an improving win rate within its operational segment.
Bears say
The financial outlook for Icon indicates a decline in EBITDA margin expectations, shifting from previous estimates of approximately 20% down to the high-19% range for both the current year and 2025. This marginal decrease reflects ongoing challenges primarily related to gross margin dynamics and highlights concerns regarding the company's capacity to meet revenue synergies from its PRA transaction. Additionally, external factors such as potential decreases in clinical trial activity, biotech funding uncertainties, and inflationary pressures further contribute to a negative outlook for the company's performance.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares